GSK to buy liver disease drug for as much as US$2 billion
The treatment developed by Boston Pharmaceuticals is ready to enter the last stage of clinical trials and has the potential to become a best-in-class medicine to treat a form of fatty liver disease, GSK said Wednesday (May 14).
GSK shares have struggled amid concern over few potential blockbuster drugs in the pipeline compared with rivals, as some of its top medicines face patent expirations.
There is growing interest in liver disease, with both Eli Lilly and Novo Nordisk working on treating the condition. The liver can get damaged by a build-up of fat or from alcohol use, and there are few treatment options. Though the medicine GSK is buying could help with both, for now it's in development for damage caused by fat build-up – a disease known by the acronym MASH.
GSK said it will pay US$1.2 billion upfront for the drug, called efimosfermin, with potential for additional milestone payments totalling US$800 million.
Mid-stage trial data on efimosfermin showed a once a month injected dose rapidly reversed liver fibrosis and stopped it progressing. BLOOMBERG
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
a day ago
- Business Times
Australian biotech giant CSL to spin off vaccine unit Seqirus, cut 15% of workforce
[SYDNEY] Australian biotech giant CSL said that it will spin off its Seqirus vaccine business into a separately listed company as part of a restructure that will see it reduce its workforce by as much as 15 per cent and cut costs by around US$500 million a year. CSL Seqirus, which makes seasonal influenza vaccines, contributed US$2.2 billion of the firm's total revenue of US$15.6 billion in the 12 months ended Jun 30, the Melbourne-based company said on Tuesday (Aug 19). Net profit rose 17 per cent to US$3 billion, just above analyst estimates of US$2.97 billion. Seqirus will list on the Australian securities exchange by the end of this fiscal year. The spinoff will give Seqirus, which will be chaired by Gordon Naylor, 'autonomy to set an independent strategic direction, including capitalising on potential opportunities that may arise in a highly dynamic vaccines market, as well as reducing complexity, making the business more agile and efficient to manage', CSL said. CSL also closed 22 underperforming US plasma centres this month, and will consolidate its research and development from 11 sites into six. The restructure will unlock US$500 million in annual savings by the end of fiscal 2028, though CSL will incur one-off restructuring costs of US$700 million to US$770 million. While CSL employs around 32,000 people, no firm number was put on the job cuts. Further details on the Seqirus spinoff will be given at CSL's capital markets day on Nov 4 to 6 in the US. CSL also plans to buy back A$750 million (S$626 million) of shares this financial year, the first step in a multi-year buyback. BLOOMBERG
Straits Times
2 days ago
- Straits Times
Novo Nordisk offers Ozempic at $640 per month to eligible US cash-paying customers
Sign up now: Get ST's newsletters delivered to your inbox GoodRx will sell Wegovy and Ozempic at US$499 monthly to eligible self-paying patients. BAGSVAERD - Novo Nordisk said on Aug 18 it was offering its diabetes drug Ozempic for US$499 (S$640.83) per month to eligible cash-paying patients with type 2 diabetes in the US via its own pharmacy, a tie-up with telehealth service GoodRx and other platforms. US-listed shares of the Danish drugmaker were up 5.3 per cent, while shares of GoodRx rose 34.2 per cent. Novo and rival Eli Lilly have expanded into direct-to-consumer sales for the highly effective and sought-after medicines, in part due to competition from online telehealth companies and pharmacies that sell cheaper compounded versions. Novo already sells Wegovy, the weight-loss version of Ozempic, through its NovoCare pharmacy for US$499. The latest offer is aimed at patients who do not have insurance coverage. Its shares were also trading higher after Wegovy secured US FDA approval for the liver disease metabolic dysfunction-associated steatohepatitis, or MASH, on Aug 15. GoodRx will sell Wegovy and Ozempic at US$499 monthly to eligible self-paying patients. A spokesperson for Novo said it expected Ozempic cash sales to account for about 10 per cent of total prescriptions - the same level of market penetration the company has experienced with Wegovy. Top stories Swipe. Select. Stay informed. Singapore Jobs, infrastructure and homes at the core of Singapore's resilience: Economists Business New online tools by SkillsFuture Singapore help companies plan and curate staff training Life Chinese EV brand Nio to be launched in Singapore in first quarter of 2026 Asia 2 firefighters die in building fire at Osaka's Dotonbori tourist district Singapore Driver hurt after car turns turtle in Upper Thomson accident Sport National tennis player Shaheed Alam serves up charity event to benefit migrant workers Life New Blackpink album scheduled for November, YG Entertainment confirms Singapore Jail for driver of 11-tonne garbage truck that ran over cyclist in Woodlands Novo said earlier in August it expects continued competition from copycat versions and rising pressure from Lilly. List prices for each drug in the United States are about US$1,000 per month or more, but insured patients pay far less. Eli Lilly offers single-dose vials of its weight-loss drug Zepbound on its website, LillyDirect, for US$499 per month or less, regardless of insurance status. Lilly does not sell its diabetes drug Mounjaro on LillyDirect. Novo said the new offer for Ozempic was part of ongoing efforts to explore new collaborations and approaches towards improving access to authentic semaglutide medicines. In April, it said it was working with telehealth firms Ro and LifeMD to sell Wegovy to expand access to cash-paying patients. REUTERS
Business Times
2 days ago
- Business Times
Clearbridge Health raises S$1.98 million in placement backed by Azure Capital
[SINGAPORE] Clearbridge Health has raised S$1.98 million in a placement backed by Singapore fund manager Azure Capital, among other investors, amid plans to acquire a biopharma company for US$330 million and to enter a new business. The placement of 990 million shares, at S$0.002 each, was fully taken up and has allowed Clearbridge to become debt-free, the company announced in a bourse filing on Monday (Aug 18). Other investors in the placement included family office Asdew Acquisitions and Ramesh Chandiramani, whom Clearbridge said is a veteran investor. The proceeds will be used for general working capital, including to support the planned acquisition of Elpis Biopharmaceuticals, with which Clearbridge signed a term sheet in April. Clearbridge also wants to enter the business of banking adult immune cells. In June, it announced plans to appoint an adviser for a processing and cryogenic storage facility for peripheral blood mononuclear cells. It has incorporated companies in Singapore and Hong Kong to prepare the launch. The placement proceeds will also be used for immediate business needs, and for opportunities that 'provide long-term growth and value for shareholders', said Clearbridge. The capital raise reflects Azure's confidence in Clearbridge's direction and leadership, said the fund manager's chief executive Terence Wong. 'The company's transformation into a debt-free entity, coupled with promising future opportunities, presents a compelling investment proposition,' he said. Clearbridge shares ended Monday flat at S$0.004.
